<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="120837">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01676571</url>
  </required_header>
  <id_info>
    <org_study_id>14077A</org_study_id>
    <nct_id>NCT01676571</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Properties of Lu AA21004 (Vortioxetine) in Healthy Young Chinese Men and Women</brief_title>
  <official_title>A Single-centre, Open-label, Single-dose Interventional Study Investigating the Pharmacokinetic Properties of Lu AA21004 in Healthy Young Chinese Men and Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rationale for this pharmacokinetic (PK) study is to determine the PK parameters for Lu
      AA21004 (Vortioxetine) in the Chinese population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>PK AUC determination of Lu AA21004 (Vortioxetine)</measure>
    <time_frame>11 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Cmax determination of Lu AA21004 (Vortioxetine)</measure>
    <time_frame>11 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximum observed concentration (Cmax)</description>
  </primary_outcome>
  <other_outcome>
    <measure>PK MR determination of metabolites Lu AA34443 and Lu AA39835</measure>
    <time_frame>11 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Metabolic ratio (MR)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with adverse events as a measure of safety and tolerability</measure>
    <time_frame>11 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lu AA21004</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AA21004</intervention_name>
    <description>10 mg immediate-release (IR), one single dose, orally</description>
    <arm_group_label>Lu AA21004</arm_group_label>
    <other_name>Vortioxetine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject is a Chinese man or woman

          -  The subject is, in the opinion of the investigator, generally healthy

          -  If female, the subject must have a negative pregnancy test at screening and baseline,
             and agree not to try to become pregnant from Screening until after the Follow-up
             Visit

        Exclusion Criteria:

          -  The subject is, in the opinion of the investigator, unlikely to comply with the
             clinical study protocol or is unsuitable for any other reason.

        Other inclusion and exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CN001</name>
      <address>
        <city>Tianjin</city>
        <zip>300457</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 15, 2013</lastchanged_date>
  <firstreceived_date>August 29, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
